ExCellBio Honored on Forbes List: A Decade of Dedication Leads to Breakthrough Success

Recently, ExCellBio was awarded the title of "2025 Forbes China Industry Leader" at the "2025 Sullivan China Entrepreneurs Annual Conference & Forbes China Industry Innovation Pioneer Awards Ceremony." Emerging from the Taicang Bay, this company has spent a decade charting the rise of China’s upstream biopharmaceutical industry.

01 South American Fetal Bovine Serum: From Pioneer to Industry Leader

After thorough evaluations of environments and serum quality in Australia, China, and Uruguay, ExCellBio identified Uruguay—a country certified by the World Organisation for Animal Health (OIE) as free of foot-and-mouth disease—as an ideal source. Uruguay’s pristine natural environment, abundant resources, and strict prohibitions on antibiotics and hormones during cattle growth ensured high-quality serum.

To refine its products, ExCellBio recruited global talent and established a full-chain system encompassing ranch blood collection, production, overseas quality control, cold-chain logistics, and domestic testing. It built serum factories in China, Uruguay, and Australia, becoming the only Chinese company with dual factories in South America. Through continuous R&D, ExCellBio’s FBS gained international recognition for its "stablebloodborne" "consistent batches" and "reliable supply", earning membership in the International Serum Industry Association (ISIA)—the first Chinese company to do so.

Today, ExCellBio's clients include thousands of top-tier biopharmaceutical firms, cell therapy companies, CRO/CDMOs, and research institutions, such as WuXi AppTec, Innovent, and HENGRUI. Its products are cited in over 3,500 high-impact SCI papers (with maximum impact factors exceeding 60).

02 Serum-Free Media: A Global Standard-Setting Trailblazers

As biopharmaceuticals flourish and regulatory safety requirements tighten, serum-free media (SFM),a critical raw material akin to chips in tech, has gained prominence. ExCellBio is developing SFM technologies to meet this demand.

ExCellBio’s SFM portfolio includes T-cell SFM, NK-cell SFM, CHO-cell SFM, MSC SFM, HEK293 SFM, and serum-free cell freezing solutions. With robust R&D, efficient production, strict quality control, and digital factory management, its products compete globally. The company holds nearly 100 patents and leads in GMP-grade cell/gene therapy media and customized antibody media.

Notably, ExCellBio’s T-cell and NK-cell SFM rank among the world’s best, supporting multiple FDA and CDE IND approvals. Its diversified portfolio (FBS, SFM, biopharmaceutical residue detection kits) serves research, cell therapy, antibody drugs, and vaccines. Certifications like ISO, GMP, EDQM, and DMF have integrated its products into global supply chains, driving valuation growth as a biopharmaceutical upstream benchmark.

03 Global Expansion: in China for global

The biopharmaceutical sector has achieved transformative innovation and productivity gains. Against this backdrop, global expansion is inevitable.

ExCellBio is a trailblazer in this journey. In 2017, it established its first Uruguayan factory, MVDMART S.A., followed by a $20 million investment in 2021 to build ARTICA—a second, higher-standard facility with an annual capacity of 150,000 liters. Uruguay now serves as ExCellBio’s global bloodborne hub.

The company operates management and sales centers in Shanghai, Beijing, Guangzhou, Shenzhen, Hong Kong, Nanjing, Hangzhou, Wuhan, Chengdu, Jinan, and Xi’an, with subsidiaries in the U.S., Australia, and Uruguay. Founder Chen Xu’s visionary leadership has laid a strong foundation for global growth.

"Developing Our biological reagents and elevating Our companies in the global industrial chain remains our mission." says Chairman Chen Xu. By overcoming technological bottlenecks, ExCellBio continues its journey.